HeartPoint Global, a Florida-based healthcare technology company focused on improving patient access to high-quality technology, won the Shark Take Innovation Competition at TCT 2023 with its Intellistent multi-lumen stent system. The device, already patented in more than 20 countries, is designed to help cardiologists treat pulmonary arterial hypertension (PAH) in congenital heart disease patients by allowing for the adjustment of blood flow into the patient’s heart-lung system.
According to HeartPoint Global, the minimally invasive device was designed to deliver benefits comparable to what is typically seen with surgical treatment. It may also serve as a bridge to surgery for some cardiac patients.
“We are deeply honored to be bestowed with this prestigious award,” Seth Bogner, HeartPoint Global’s chairman and CEO, said in a prepared statement. “TCT stands as a pinnacle platform for highlighting innovation in cardiovascular medicine. Having our technology acknowledged by such a distinguished panel of judges is truly humbling. We are eager to forge ahead with HeartPoint Global's in-human trials and anticipate its substantial clinical impact in the future.”
Elena K. Amin, MBChB, a pediatric cardiologist with UCSF Health, presented her team’s data during the Shark Tank competition. Six finalists were selected to attend TCT 2023 and present their technology, and HeartPoint Global took home a $200,000 prize for winning the competition. A panel of physicians, investors and industry experts served as judges.
HeartPoint Global plans on using the technology behind the Intellistent to treat numerous other conditions in the future. Click here to read an analysis of the technology published in JACC: Basic to Translational Science, an American College of Cardiology journal.[1]
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.